Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to ...

IIM Ahmedabad and Novo Nordisk India collaborate for five years to strengthen obesity care in India through capacity building ...